FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011643393> ?p ?o ?g. }

• W2011643393 endingPage "1122" @default.
• W2011643393 startingPage "1103" @default.
• W2011643393 abstract "In recent studies using a rat aortic balloon occlusion model, we have demonstrated that spinal grafting of rat or human neuronal precursors or human postmitotic hNT neurons leads to progressive amelioration of spasticity and rigidity and corresponding improvement in ambulatory function. In the present study, we characterized the optimal dosing regimen and safety profile of human spinal stem cells (HSSC) when grafted into the lumbar spinal cord segments of naive immunosuppressed minipigs. Gottingen-Minnesota minipigs (18–23 kg) were anesthetized with halothane, mounted into a spine-immobilization apparatus, and received five bilateral injections of HSSC delivered in 2, 4, 6, 8, or 10 μl of media targeted into L2-L5 central gray matter (lamina VII). The total number of delivered cells ranged between 2,500 and 100,000 per injection. Animals were immunosuppressed with Prograf® for the duration of study. After cell grafting, ambulatory function was monitored daily using a Tarlov's score. Sensory functions were assessed by mechanically evoked skin twitch test. Animals survived for 6–7 weeks. Three days before sacrifice animals received daily injections of bromodeoxyuridine (100 mg/kg; IV) and were then transcardially perfused with 4% paraformaldehyde. Th12-L6 spinal column was then dissected; the spinal cord was removed and scanned with MRI. Lumbar transverse spinal cord sections were then cut and stained with a combination of human-specific (hNUMA, hMOC, hNSE, hSYN) or nonspecific (DCX, MAP2, GABA, CHAT) antibodies. The total number of surviving cells was estimated using stereological quantification. During the first 12–24 h after cell grafting, a modest motor weakness was observed in three of eight animals but was no longer present at 4 days to 7 weeks. No sensory dysfunction was seen at any time point. Postmortem MRI scans revealed the presence of the individual grafts in the targeted spinal cord areas. Histological examination of spinal cord sections revealed the presence of hNUMA-immunoreactive grafted cells distributed between the base of the dorsal horn and the ventral horn. In all grafts intense hMOC, DCX, and hSYN immunoreactivity in grafted cells was seen. In addition, a rich axodendritic network of DCX-positive processes was identified extending 300–700 μm from the grafts. On average, 45% of hNUMA-positive neurons were GABA immunoreactive. Stereological analysis of hNUMA-positive cells showed an average of 2.5- to 3-fold increase in number of surviving cells compared with the number of injected cells. Analysis of spinal structural morphology showed that in animals injected with more than 50,000 cells/injection or volumes of injectate higher than 6 μl/injection there was tissue expansion and disruption of the local axodendritic network. Based on these data the safe total number of injected cells and volume of injectate were determined to be 30,000 cells delivered in ≤6 μl of media. These data demonstrate that highly reproducible delivery of a potential cell therapeutic candidate into spinal parenchyma can be achieved across a wide range of cell doses by direct intraspinal injections. The resulting grafts uniformly showed robust cell survival and progressive neuronal maturation." @default.
• W2011643393 created "2016-06-24" @default.
• W2011643393 creator A5011645736 @default.
• W2011643393 creator A5033066596 @default.
• W2011643393 creator A5033824166 @default.
• W2011643393 creator A5038562478 @default.
• W2011643393 creator A5040197822 @default.
• W2011643393 creator A5042389999 @default.
• W2011643393 creator A5044193893 @default.
• W2011643393 creator A5048603317 @default.
• W2011643393 creator A5051556243 @default.
• W2011643393 creator A5052600113 @default.
• W2011643393 creator A5052618725 @default.
• W2011643393 creator A5073265097 @default.
• W2011643393 creator A5078525449 @default.
• W2011643393 creator A5089935033 @default.
• W2011643393 creator A5091197858 @default.
• W2011643393 date "2010-09-01" @default.
• W2011643393 modified "2023-10-17" @default.
• W2011643393 title "Analysis of Dosing Regimen and Reproducibility of Intraspinal Grafting of Human Spinal Stem Cells in Immunosuppressed Minipigs" @default.
• W2011643393 cites W1574222606 @default.
• W2011643393 cites W1932898357 @default.
• W2011643393 cites W1971219758 @default.
• W2011643393 cites W1972456044 @default.
• W2011643393 cites W1972553438 @default.
• W2011643393 cites W1972910127 @default.
• W2011643393 cites W1973456315 @default.
• W2011643393 cites W1974190675 @default.
• W2011643393 cites W1976256963 @default.
• W2011643393 cites W1979725545 @default.
• W2011643393 cites W1984523641 @default.
• W2011643393 cites W1986346910 @default.
• W2011643393 cites W1993019240 @default.
• W2011643393 cites W2000928738 @default.
• W2011643393 cites W2009987251 @default.
• W2011643393 cites W2010505933 @default.
• W2011643393 cites W2019076531 @default.
• W2011643393 cites W2020539766 @default.
• W2011643393 cites W2028190741 @default.
• W2011643393 cites W2032649493 @default.
• W2011643393 cites W2038311122 @default.
• W2011643393 cites W2039641888 @default.
• W2011643393 cites W2040797118 @default.
• W2011643393 cites W2042138711 @default.
• W2011643393 cites W2046265664 @default.
• W2011643393 cites W2049733463 @default.
• W2011643393 cites W2052950181 @default.
• W2011643393 cites W2061339838 @default.
• W2011643393 cites W2063511140 @default.
• W2011643393 cites W2067019666 @default.
• W2011643393 cites W2068840175 @default.
• W2011643393 cites W2080950947 @default.
• W2011643393 cites W2083283021 @default.
• W2011643393 cites W2090612180 @default.
• W2011643393 cites W2097509747 @default.
• W2011643393 cites W2108324820 @default.
• W2011643393 cites W2111405228 @default.
• W2011643393 cites W2113724937 @default.
• W2011643393 cites W2117224659 @default.
• W2011643393 cites W2117712478 @default.
• W2011643393 cites W2123150624 @default.
• W2011643393 cites W2135802435 @default.
• W2011643393 cites W2145928890 @default.
• W2011643393 cites W2153286899 @default.
• W2011643393 cites W2154549928 @default.
• W2011643393 cites W2325308917 @default.
• W2011643393 cites W2600825804 @default.
• W2011643393 doi "https://doi.org/10.3727/096368910x503406" @default.
• W2011643393 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20412634" @default.
• W2011643393 hasPublicationYear "2010" @default.
• W2011643393 type Work @default.
• W2011643393 sameAs 2011643393 @default.
• W2011643393 citedByCount "50" @default.
• W2011643393 countsByYear W20116433932012 @default.
• W2011643393 countsByYear W20116433932013 @default.
• W2011643393 countsByYear W20116433932014 @default.
• W2011643393 countsByYear W20116433932015 @default.
• W2011643393 countsByYear W20116433932016 @default.
• W2011643393 countsByYear W20116433932017 @default.
• W2011643393 countsByYear W20116433932018 @default.
• W2011643393 countsByYear W20116433932019 @default.
• W2011643393 countsByYear W20116433932020 @default.
• W2011643393 countsByYear W20116433932021 @default.
• W2011643393 countsByYear W20116433932022 @default.
• W2011643393 countsByYear W20116433932023 @default.
• W2011643393 crossrefType "journal-article" @default.
• W2011643393 hasAuthorship W2011643393A5011645736 @default.
• W2011643393 hasAuthorship W2011643393A5033066596 @default.
• W2011643393 hasAuthorship W2011643393A5033824166 @default.
• W2011643393 hasAuthorship W2011643393A5038562478 @default.
• W2011643393 hasAuthorship W2011643393A5040197822 @default.
• W2011643393 hasAuthorship W2011643393A5042389999 @default.
• W2011643393 hasAuthorship W2011643393A5044193893 @default.
• W2011643393 hasAuthorship W2011643393A5048603317 @default.
• W2011643393 hasAuthorship W2011643393A5051556243 @default.
• W2011643393 hasAuthorship W2011643393A5052600113 @default.
• W2011643393 hasAuthorship W2011643393A5052618725 @default.
• W2011643393 hasAuthorship W2011643393A5073265097 @default.

• next